Pharma and Biotech Growth Drives 4.5% CAGR in Efficacy Testing Market Through 2032

According to the latest market research study published by P&S Intelligence, the global efficacy testing market, valued at USD 389.9 million in 2024, is projected to grow steadily to USD 548.1 million by 2032, registering a CAGR of 4.5% (2025–2032). This surge reflects the increasing demand for higher quality biologics, rising regulatory requirements, and the widespread adoption of innovative testing models.

Efficacy testing plays a critical role in validating pharmaceuticals, biologics, cosmetics, personal care products, and medical devices. With heightened scrutiny from agencies like the FDA, EMA, WHO, and national regulators, manufacturers across the globe are investing in robust testing methods to meet stringent compliance standards and patient safety expectations.

Key Market Growth Drivers

• Shift Toward Advanced In Vitro and Alternative Models: Companies are rapidly moving away from animal testing, embracing 3D cell culture, organ-on-a-chip technologies, AI-driven models, and high-throughput screening. Global regulators are recognizing these faster, safer, and more human-relevant methods.


• Rising Biologics & Biosimilars Demand: Biologics sales are expected to reach USD 745.1 billion by 2030, fueling the need for precise efficacy validation. With more patents expiring, biosimilar development is expanding, creating opportunities for advanced testing providers.


• Government & Industry Collaboration: Regulatory authorities are simplifying pathways for biosimilars and monoclonal antibodies, while initiatives from the FDA, EMA, and international alliances accelerate the adoption of alternative, next-generation testing technologies.

Get the sample copy of this report: https://www.psmarketresearch.com/market-analysis/efficacy-testing-market/report-sample

Market Segmentation Highlights

• By Service Type:
  
  
  
  • Disinfectant analytics dominated with 70% market share in 2024, driven by rising hygiene awareness.
  
  
  • Antimicrobial testing is projected to grow faster (5.5% CAGR), boosted by rapid microbial detection technologies.
  
  
  
  


• By Application:
  
  
  
  • Biopharmaceuticals held the largest share (45%) due to increasing sterility and safety requirements.
  
  
  • Cosmetics & personal care will expand fastest, supported by consumer demand for clinically validated, clean-label products.
  
  
  
  

Regional Dynamics

• North America led with 52% share in 2024, backed by advanced infrastructure, strict regulations, and strong R&D investments.


• Asia-Pacific (APAC) is the fastest-growing region, with China and India emerging as high-potential markets due to regulatory tightening, cost-effective testing environments, and booming demand for skincare and personal care efficacy validation.

Competitive Landscape

The market remains fragmented, with key players including:
Charles River Laboratories, WuXi AppTec, SGS, Eurofins Scientific, Intertek Group plc, Nelson Laboratories, Lucideon Limited, Microbac Laboratories, Pacific BioLabs, Almac Group, and Accugen Laboratories Inc.

Notable industry developments include:

• Charles River Laboratories’ USD 500M AMAP investment in alternative, animal-free testing methods (2024).


• Almac Group’s EUR 65M manufacturing expansion in Northern Ireland (2025).


• FDA and EMA initiatives to accelerate AI-based and organ-on-chip testing platforms.

Outlook

With a growing emphasis on patient safety, regulatory compliance, biologics development, and cruelty-free testing models, the efficacy testing market is positioned for strong and sustainable growth. Manufacturers and service providers that invest in rapid, AI-powered, and in vitro platforms are expected to lead the next phase of transformation in this evolving sector.

About P&S Intelligence

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.